Abstract: The present disclosure provides yeast screening system/s and methods for screening of candidate therapeutic compound/s for treating, at least one proteniopathy and/or protein misfolding disorder. More specifically, the present disclosure provides systems and methods for identifying a therapeutic compound that inhibit Hcy fibril formation and uses thereof in treating Alzheimer's disease.

Abstract: The invention relates to in vivo systems and high throughput screening platform for drugs applicable in inborn error of metabolism (IEM) disorders. More specifically, the invention provides yeast screening system of candidate therapeutic compounds applicable in IEM disorders associated with accumulation of at least one metabolite. The systems of the invention comprise yeast cell/s that carry at least one manipulation in at least one yeast metabolic pathway, that leads to accumulation of said metabolite.